Noxopharm (ASX:NOX) has reached a significant milestone in its first-in-human trial of SOF-SKN, announcing that the initial multiple-dose cohort in the HERACLES study has been completed with no safety concerns identified.

LTR Pharma (ASX:LTP) has secured ethics approval for the next stage of clinical development of its fast-acting erectile dysfunction therapy, paving the way for recruitment to begin early next year and marking another step in the company’s expansion into global markets.

A team of Melbourne researchers has uncovered how subtle electrical signals can direct stem cell behaviour, an advance that could reshape the future of tissue engineering, regenerative medicine, and the development of lab-grown organs.

Island Pharmaceuticals (ASX:ILA) has strengthened its financial position, announcing that directors and substantial shareholders have exercised more than 14.4 million options, delivering just over $1 million in new capital to support the company’s antiviral development programs.

BCAL Diagnostics (ASX:BDX) has taken a significant step toward strengthening clinical confidence in its flagship breast cancer diagnostic, announcing national ethics approval for a large-scale registry that will track outcomes for up to 24,000 Australian women.

AusBiotech is pleased to share an opportunity for Australia’s life sciences community to hear directly from AstraZeneca’s global Search and Evaluation leaders.

Immutep (ASX:IMM) will present new clinical results from its AIPAC-003 Phase 2 trial at next week’s San Antonio Breast Cancer Symposium, highlighting encouraging response rates and clear signs of immune activation in heavily pretreated metastatic breast cancer patients.

Imugene (ASX:IMU) has released new clinical data showing an 82 per cent overall response rate in its Phase 1b trial of azer-cel, the company’s allogeneic, off-the-shelf CD19 CAR T therapy for patients with relapsed or refractory diffuse large B-cell lymphoma.

Entropy Neurodynamics (ASX:ENP) has marked a significant clinical milestone, successfully administering the first dose of its proprietary psilocin formulation, TRP-8803, in a trial targeting binge eating disorder.

CLINUVEL Pharmaceuticals (ASX:CUV) has taken a significant step toward expanding its product portfolio, confirming it is planning to lodge a European regulatory submission for its second pharmaceutical product, NEURACTHEL Instant, by mid-2026.

Chimeric Therapeutics (ASX:CHM) has reassured investors of its strategic direction and clinical momentum, announcing a forthcoming refresh of its board and reaffirming backing from major shareholders following its Annual General Meeting held on 25 November.

Cartherics has announced a significant leadership transition, appointing biotechnology executive and company co-founder Dr Ian Nisbet as Chief Executive Officer as the Melbourne-based cell therapy developer prepares for its next phase of growth.

Melbourne is putting its biomedical and health innovation ecosystem on display as delegates from across Australia and overseas gather in the city for the National Health and Innovation Precincts Summit, the first time the annual event has been hosted in Victoria.

Tetratherix (ASX:TTX) has announced a significant step forward for its US-based joint venture BioOptix, with the ophthalmic biomaterials company signing a development agreement with global eye-care leader Alcon Research.

The agreement brings together Imugene’s oncolytic virus CF33-CD19 (onCARlytics) and JW’s CD19-directed autologous CAR-T therapy, Carteyva, in a program that spans preclinical studies through to a Phase 1 investigator-initiated clinical trial in China.

Neurizon Therapeutics (ASX:NUZ) Chair Sergio Duchini has told shareholders the company is entering a decisive phase in its mission to bring new treatments to patients with neurodegenerative diseases, describing the past year as one of disciplined execution, strengthened governance, and meaningful scientific progress.

Syntara (ASX:SNT) has taken a significant step forward in the development of its next-generation topical anti-fibrotic therapy, announcing that its lead pan-lysyl oxidase inhibitor, SNT-9465, has completed a Phase 1a clinical trial and will now progress into a Phase 1b study in patients with hypertrophic scars.